Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis C (HCV) Genotype 1 Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 1 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis C (HCV) Genotype 1 Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 271 of 271 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Sample Detail 2 | Test 3 | Test Data 3 | Sample Detail 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Information 2 | Additional Data 2 | Additional Detail 2 | Additional Information 3 | Additional Data 3 | Additional Information 4 | Additional Data 4 | Additional Detail 4 | Additional Information 5 | Additional Data 5 | Additional Detail 5 | Additional Information 6 | Additional Data 6 | Additional Detail 6 | Additional Information 7 | Additional Data 7 | Additional Detail 7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS12-0177 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 1.00 | $95.00 | 55 Y | F | U/A | <-70°C | 19-Jun-12 | Real-Time PCR | 183,437 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | Depression | Additional Testing | ALT: 33 AST: 57 ALP: 122 LDH: 480 Bilirubin: 3.95 Serum Creatinine: 0.62 mg/dL Liver Disease Diagnosis: 2009 Hepatocellular Carcinoma 2012 | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0367 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 78 Y | M | U/A | <-70°C | 27-Jun-12 | Real-Time PCR | 86,732 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Fatigue | Additional Testing | ALT: 22; AST: 23; ALP: 130; Bilirubin: 0.40; Serum Creatinine: 0.90 mg/dL; Liver Disease Diagnosis: 2007; Hepatocellular Carcinoma 2012 | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0375 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 74 Y | F | U/A | <-70°C | 19-Jul-12 | Real-Time PCR | 385,711 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | Fatigue; Jaundice; Nausea | Additional Testing | ALT: 42; AST: 27; Bilirubin: 0.70; Serum Creatinine: 1.06 mg/dL; Liver Disease Diagnosis: 1989; Hepatic Cirrhosis 2012 | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0379 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 66 Y | F | U/A | <-70°C | 20-Jul-12 | Real-Time PCR | 75,041 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | Fatigue; Abdominal pain | Additional Testing | ALT: 33; AST: 108; ALP: 196; LDH: 437; Bilirubin: 1.72; Serum Creatinine: 0.86 mg/dL; Liver Disease Diagnosis: 2006; Hepatic Cirrhosis 2012 | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0387 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 74 Y | M | U/A | <-70°C | 27-Jul-12 | Real-Time PCR | 138,611 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Joint pain | Additional Testing | ALT: 46; AST: 53; ALP: 126; LDH: 271; Bilirubin: 4.50; Serum Creatinine: 1.56 mg/dL; Liver Disease Diagnosis: 2007; Cirrhosis 2012 | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0391 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 80 Y | M | U/A | <-70°C | 03-Aug-12 | Real-Time PCR | 302,904 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 28; AST: 44; ALP: 52; LDH: 549; Bilirubin: 0.66; Serum Creatinine: 1.78 mg/dL; Cirrhosis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0393 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 73 Y | F | U/A | <-70°C | 02-Aug-12 | Real-Time PCR | 15,000 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Household Contact; Dental Care | Symptoms | Joint pain | Additional Testing | ALT: 35; AST: 57; ALP: 95; Bilirubin: 0.65; Serum Creatinine: 0.71 mg/dL; Liver Disease Diagnosis: 1994; Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0395 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 2.00 | $95.00 | 80 Y | M | U/A | <-70°C | 10-Aug-12 | Real-Time PCR | 738,478 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | No symptoms | Additional Testing | ALT: 41; AST: 80; ALP: 131; LDH: 307; Bilirubin: 0.40; Serum Creatinine: 1.19 mg/dL; Liver Disease Diagnosis: 1997; Cirrhosis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0398 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 3.00 | $95.00 | 42 Y | M | U/A | <-70°C | 04-Sep-12 | Qiagen RT PCR | 762,550 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion; Surgery | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Nausea | Additional Testing | ALT: 284; AST: 154; ALP: 79; Bilirubin: 0.68; Serum Creatinine: 0.82 mg/dL; Liver Disease Diagnosis: 2012; Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0399 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 3.00 | $95.00 | 75 Y | M | U/A | <-70°C | 05-Sep-12 | Real-Time PCR | 274,773 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Jaundice | Additional Testing | ALT: 23; AST: 62; ALP: 116; LDH: 347; Bilirubin: 0.80; Serum Creatinine: 1.151 mg/dL; Liver Disease Diagnosis: 2009; Hepatocellular carcinoma | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0403 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 66 Y | M | White | <-70°C | 10-Sep-12 | Real-Time PCR | 660,631 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 74; AST: 69; Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0404 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 64 Y | F | White | <-70°C | 10-Sep-12 | Real-Time PCR | 66,186 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Household Contact | Symptoms | Jaundice | Additional Testing | ALT: 71; AST: 39; Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0405 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 6.00 | $95.00 | 78 Y | M | White | <-70°C | 10-Sep-12 | Real-Time PCR | 104,000 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Jaundice; Joint pain; Sleep disturbances | Additional Testing | ALT: 72; AST: 80; Bilirubin: 1.9; Serum Creatinine: 1.0 mg/dL; Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0406 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 1.00 | $95.00 | 80 Y | M | White | <-70°C | 11-Sep-12 | Real-Time PCR | 807,280 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 107; AST: 37; ALP: 82; LDH: 354; Bilirubin: 0.81; Serum Creatinine: 1.27 mg/dL; Hepatic Cirrhosis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0417 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 2.00 | $95.00 | 65 Y | F | White | <-70°C | 18-Sep-12 | Real-Time PCR | 767,000 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | Fatigue; Jaundice; Nausea | Additional Testing | ALT: 184; AST: 187; ALP: 135; Bilirubin: 0.79; Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-0419 | Hepatitis C (HCV) Genotype 1 | Italy | Plasma | 1.00 | 2.00 | $95.00 | 74 Y | M | White | <-70°C | 20-Sep-12 | Real-Time PCR | 11,900 IU/mL | Siemens TruGene HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Joint pain | Additional Testing | ALT: 161; AST: 144; ALP: 166; LDH: 381; Bilirubin: 0.87; Serum Creatinine: 1.14 mg/dL; Hepatocellular Carcinoma | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-6282 | Hepatitis C (HCV) Genotype 1 | USA | Serum | 0.25 | 1.00 | $95.00 | 38 Y | M | Cuban/Caucasian | <-70°C | 04-Feb-13 | Roche cobas | 1,009,903 IU/mL | Innogenetics Versant HCV | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue | Additional Testing | ALT: 43; AST: 34; ALP: 76; Bilirubin: 0.5 | Hepatitis Serology | Hep C Antibody+; HBsAg- | |||||||||||||||
| DLS12-6299 | Hepatitis C (HCV) Genotype 1 | Russia | Plasma | 1.00 | 7.00 | $95.00 | 37 Y | F | White | <-70°C | 08-Oct-13 | Roche cobas | 6,800,000 IU/mL | Genotype | 1b | Per Medical Records | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Abdominal pain | Additional Testing | ALT: 37; AST: 26; ALP: 72; LDH: 168; Bilirubin: 0.4 mg/dL; Serum Creatinine: 0.71 mg/dL; HAI: Staging 0 Grading 3 | ||||||||||||||||
| DLS12-6300 | Hepatitis C (HCV) Genotype 1 | Germany | Plasma | 1.25 | 1.00 | $95.00 | 51 Y | M | White | <-70°C | 11-Oct-13 | Roche cobas | 5,500,000 IU/mL | Genotype | 1a | Per Medical Records | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | No symptoms | Additional Testing | ALT: 12; AST: 27; ALP: 39; LDH: 186; Bilirubin: 0.3 mg/dL; Serum Creatinine: 0.79 mg/dL; HAI: Staging 1 Grading 0 | ||||||||||||||||
| DLS12-6349 | Hepatitis C (HCV) Genotype 1 | USA | Plasma | 1.25 | 1.00 | $95.00 | 54 Y | M | White | <-70°C | 26-Feb-13 | Roche cobas | 1,717,375 IU/mL | Genotype | 1a | Per Medical Records | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Occupational Working Firefighter | Symptoms | Fatigue; Depression | Additional Testing | ALT: 42; AST: 35; ALP: 81; Biopsy: G1 S1 | ||||||||||||||||
| DLS12-7464 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 2.00 | $40.00 | 45 Y | M | U/A | <-70°C | 16-Jul-11 | Roche cobas | 9,704,643 IU/mL | HCV Ct Value - 12.3 | Innogenetics INNO-LIPA | 1a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 6.24 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7465 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 4.00 | $40.00 | 41 Y | F | U/A | <-70°C | 20-Jan-12 | Roche cobas | 3,538,653 IU/mL | HCV Ct Value - 14 | Innogenetics INNO-LIPA | 1a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 6.19 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7466 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 4.00 | $40.00 | 44 Y | F | U/A | <-70°C | 03-Mar-12 | Roche cobas | 6,270,332 IU/mL | HCV Ct Value - 14 | Innogenetics INNO-LIPA | 1a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 9.23 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7467 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 7.00 | $40.00 | 39 Y | M | U/A | <-70°C | 07-Mar-12 | Roche cobas | 916,713 IU/mL | HCV Ct Value - 17 | Innogenetics INNO-LIPA | 1a | Immunoblot | C1(4+) C2(4+) E2(3+) NS3(4+) NS4(4+) NS5(-) | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 7.22 (Abbott PRISM) | ||||||||||||||||||||
| DLS12-7469 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 5.00 | $40.00 | 45 Y | M | U/A | <-70°C | 22-Jun-12 | Roche cobas | 685,173 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 5.32 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7470 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 8.00 | $40.00 | 50 Y | M | U/A | <-70°C | 13-Jun-12 | Roche cobas | 8,795,263 IU/mL | HCV Ct Value - 11 | Innogenetics INNO-LIPA | 1a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 8.09 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7471 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 12.00 | $40.00 | 39 Y | M | U/A | <-70°C | 16-Jun-11 | Roche cobas | 289,778 IU/mL | HCV Ct Value - 11 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 7.79 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7472 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 9.00 | $40.00 | 47 Y | F | U/A | <-70°C | 22-Jul-11 | Roche cobas | 87,452 IU/mL | HCV Ct Value - 23 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 5.35 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7473 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 10.00 | $40.00 | 44 Y | F | U/A | <-70°C | 11-Aug-11 | Roche cobas | 665,224 IU/mL | HCV Ct Value - 21 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 5.05 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7474 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 10.00 | $40.00 | 35 Y | M | U/A | <-70°C | 20-Jan-12 | Roche cobas | 1,289,638 IU/mL | HCV Ct Value - 14 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 6.15 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7475 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 12.00 | $40.00 | 43 Y | M | U/A | <-70°C | 28-Jan-12 | Roche cobas | 3,951,173 IU/mL | HCV Ct Value - 19 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 7.2 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7476 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 12.00 | $40.00 | 62 Y | F | U/A | <-70°C | 23-Apr-12 | Roche cobas | 33,879 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 8.33 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-7477 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 10.00 | $40.00 | 45 Y | M | U/A | <-70°C | 24-Apr-12 | Roche cobas | 611,136 IU/mL | HCV Ct Value - 19 | Innogenetics INNO-LIPA | 1b | Immunoblot | C1(4+) C2(3+) E2(3+) NS3(3+) NS4(-) NS5(-) | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 5.18 (Abbott PRISM) | ||||||||||||||||||||
| DLS12-7479 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 7.00 | $40.00 | 45 Y | M | U/A | <-70°C | 20-Jun-12 | Roche cobas | 4,467,154 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 7.91 (Abbott PRISM) | ||||||||||||||||||||||
| DLS12-8113 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 2.00 | $40.00 | 40 Y | M | U/A | <-70°C | 09-Jun-12 | Roche cobas | 7,088,335 IU/mL | HCV Ct Value - 11 | Innogenetics INNO-LIPA | 1b | Immunoblot | C1(4+) C2(3+) E2(1+) NS3(4+) NS4(4+) NS5(4+) HBsAg (+) HBV DNA (-) | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 9.03 Abbott PRISM | ||||||||||||||||||||
| DLS12-8115 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 12.00 | $40.00 | 44 Y | F | U/A | <-70°C | 13-Jul-12 | Roche cobas | 2,642,943 IU/mL | HCV Ct Value - 11 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 7.85 Abbott PRISM | ||||||||||||||||||||||
| DLS12-8116 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 9.00 | $40.00 | 54 Y | M | U/A | <-70°C | 28-Jul-12 | Roche cobas | 1,204,692 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1b | Immunoblot | C1(3+) C2(2+) E2(-) NS3(4+) NS4(4+) NS5(2+) | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 6.09 Abbott PRISM | ||||||||||||||||||||
| DLS12-8117 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 8.00 | $40.00 | 47 Y | M | U/A | <-70°C | 18-Aug-12 | Roche cobas | 491,061 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 5.64 Abbott PRISM | ||||||||||||||||||||||
| DLS12-8118 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 11.00 | $40.00 | 44 Y | M | U/A | <-70°C | 25-Aug-12 | Roche cobas | 1,179,766 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1b | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 7.87 Abbott PRISM | ||||||||||||||||||||||
| DLS12-8349 | Hepatitis C (HCV) Genotype 1 | Germany | Plasma | 1.00 | 2.00 | $95.00 | 39 Y | M | White | <-70°C | 13-Mar-13 | Roche cobas | 3,400,000 IU/mL | Research Use Only In-House | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | No symptoms | Additional Testing | ALT: 90; AST: 49; ALP: 85; Bilirubin: 0.5; Fibroscan 3.7 kPa; Serum Creatinine: 0.9 mg/dL | Hepatitis Serology | HBcAg-; anti-HBc+; anti-HBs+; anti-HCV+ | |||||||||||||||
| DLS12-8357 | Hepatitis C (HCV) Genotype 1 | Germany | Plasma | 1.00 | 8.00 | $95.00 | 60 Y | F | White | <-70°C | 21-Jan-13 | Roche cobas | 380,000 IU/mL | Research Use Only In-House | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Itching; Sleep disturbances; Fatigue | Additional Testing | ALT: 37; AST: 48; ALP: 114; Bilirubin: 0.4; Serum Creatinine: 1.16 mg/dL | |||||||||||||||||
| DLS12-8359 | Hepatitis C (HCV) Genotype 1 | Germany | Plasma | 0.50 | 2.00 | $95.00 | 51 Y | F | White | <-70°C | 01-Feb-13 | Roche cobas | 750,000 IU/mL | Research Use Only In-House | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Abdominal pain; Fatigue; Sleep disturbances; Depression | Additional Testing | ALT: 27.9; AST: 27.2; ALP: 109; LDH: 238; Bilirubin: 0.4; Serum Creatinine: 0.67 mg/dL | |||||||||||||||||
| DLS12-8492 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 5.00 | $95.00 | 59 Y | F | Asian | <-70°C | 28-May-13 | Roche cobas | 24,000,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Sleep disturbances; Nausea | Additional Testing | ALT: 12; AST: 50; Bilirubin: 10.8 umol/L; Serum Creatinine: 98 umol/L; Hepatitis C | |||||||||||||||||
| DLS12-8494 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 1.00 | $95.00 | 41 Y | M | Asian | <-70°C | 23-Apr-13 | Roche cobas | 1,590,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice; Flu-like symptoms | Additional Testing | ALT: 135; AST: 125; ALP: 107; Bilirubin: 30 umol/L; Serum Creatinine: 66 umol/L | Hepatitis Serology | HBsAg- (ECLIA Cobas 6000) | |||||||||||||||
| DLS12-8496 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 40 Y | M | Asian | <-70°C | 30-Jul-13 | Roche cobas | 460,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 114 U/L; AST: 73 U/L; Serum Creatinine: 7.3 umol/L | Hepatitis Serology | HBsAg+; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2008 | |||||||||||
| DLS12-8499 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 3.00 | $95.00 | 58 Y | M | Asian | <-70°C | 05-Jul-13 | Roche cobas | 1,160,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 24; AST: 95; Bilirubin: 16.1 umol/L | Hepatitis Serology | Anti HCV+ (ECLIA Cobas 6000) | |||||||||||||||
| DLS12-8501 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 1.00 | $95.00 | 41 Y | M | Asian | <-70°C | 18-Jul-13 | Roche cobas | 22,600,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Joint pain; Sleep disturbances | Additional Testing | ALT: 42; AST: 39; Serum Creatinine: 88 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | |||||||||||
| DLS12-8518 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 8.00 | $95.00 | 63 Y | F | Asian | <-70°C | 06-May-13 | Roche cobas | 978,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 103; AST: 80; Bilirubin: 9.1 umol/L; Serum Creatinine: 89 umol/L | Hepatitis Serology | HBsAg- (ECLIA Cobas 6000) | |||||||||||||||
| DLS12-8519 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 12.00 | $95.00 | 36 Y | M | Asian | <-70°C | 14-Aug-13 | Roche cobas | 35,700,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Nevirapine 200 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite | Additional Testing | ALT: 22 U/L; AST: 41 U/L; Serum Creatinine: 84 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2013 | |||||||||||
| DLS12-8523 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 15.00 | $95.00 | 33 Y | M | Asian | <-70°C | 24-Jul-13 | Roche cobas | 45,000,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 49 U/L; AST: 38 U/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2001 | |||||||||||
| DLS12-8525 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 13.00 | $95.00 | 49 Y | M | Asian | <-70°C | 24-Jul-13 | Roche cobas | 17,300,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 85 U/L; AST: 64 U/L; Serum Creatinine: 86 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | |||||||||||
| DLS12-8530 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 10.00 | $95.00 | 37 Y | M | Asian | <-70°C | 15-Jul-13 | Roche cobas | 32,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Tenofovir 300 mg; Aluvia 200/50 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Fatigue; Joint pain | Additional Testing | ALT: 25 U/L; AST: 25 U/L; Serum Creatinine: 103 umol/L | Co-Infections | HIV+ | 2006 | |||||||||||||
| DLS13-00016 | Hepatitis C (HCV) Genotype 1 | USA | Plasma | 1.00 | 1.00 | $95.00 | 68 Y | M | White | <-70°C | 17-Jan-13 | Method Not Available | 2,360,000 IU/mL | Method Not Available | 1a | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Combivir for HIV | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Weight loss | Additional Testing | ALT: 45; AST: 41; ALP: 80; Bilirubin: 0.4; Serum Creatinine: 0.89 mg/dL; LDH: 89 | Co-Infections | HIV+ | 2004 | |||||||||||||
| DLS13-00022 | Hepatitis C (HCV) Genotype 1 | USA | Serum | 0.75 | 1.00 | $95.00 | 53 Y | M | White | <-70°C | 04-Oct-12 | Roche cobas | GenMark Dx eSensor XT-8 | 1b | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue; Abdominal pain; Flu-like symptoms; Joint pain; Depression | Additional Testing | ALT: 24; AST: 51; Bilirubin: 0.1; Biopsy 7-Jul-2004; Liver Disease Diagnosis: 2003 | ||||||||||||||||||
| DLS13-01447 | Hepatitis C (HCV) Genotype 1 | USA | Serum | 1.00 | 1.00 | $95.00 | 49 Y | F | White | <-70°C | 14-Feb-13 | Quantitative HCV RNA Assay | 180,965 IU/mL | Siemens Trugene HCV | 1b | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual transmission; Rape, Sodomized | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Flu-like symptoms; Joint pain; Nausea; Depression | Additional Testing | ALT: 65; AST: 82 ALP: 148; Bilirubin: 0.61; Serum Creatinine: 0.8 mg/dL | |||||||||||||||||
| DLS13-01448 | Hepatitis C (HCV) Genotype 1 | Taiwan | Plasma | 1.00 | 1.00 | $95.00 | 54 Y | F | Asian | <-70°C | 07-Mar-13 | Roche cobas | 111,748 IU/mL | RT-PCR, reverse hybridization | 1b | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | None | Additional Testing | ALT: 31; AST: 32 ALP: 36; Bilirubin: 0.6; Serum Creatinine: 0.8 mg/dL | |||||||||||||||||
| DLS13-03326 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 8.00 | $40.00 | 51 Y | M | U/A | < -70C | 02-Jan-12 | Roche cobas | 465,532 IU/mL | HCV Ct Value - 15 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 6.41 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03330 | Hepatitis C (HCV) Genotype 1 | France | Citrated Plasma | 1.00 | 9.00 | $40.00 | 38 Y | M | U/A | < -70C | 10-Oct-12 | Roche cobas | 344,394 IU/mL | HCV Ct Value - 16 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 7.11 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03331 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 8.00 | $40.00 | 51 Y | M | U/A | < -70C | 29-Jul-07 | Roche cobas | 30,508 IU/mL | HCV Ct Value - 25 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 5.08 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03333 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 11.00 | $40.00 | 48 Y | M | U/A | < -70C | 02-Nov-12 | Roche cobas | 377,589 IU/mL | HCV Ct Value - 16 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 3.67 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | Other Testing Results | Immunoblot C1(4+) C2(4+) E2(2+) NS3(4+) NS4(4+) NS5(4+) | |||||||||||||||||
| DLS13-03334 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 11.00 | $40.00 | 18 Y | F | U/A | < -70C | 08-Jan-13 | Roche cobas | Not detected | HCV Ct Value - 12 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 6.1 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03335 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 10.00 | $40.00 | 49 Y | M | U/A | < -70C | 27-Oct-12 | Roche cobas | 538,277 IU/mL | HCV Ct Value - 16 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 7.1 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03339 | Hepatitis C (HCV) Genotype 1 | Spain | Citrated Plasma | 1.00 | 21.00 | $40.00 | 26 Y | F | U/A | < -70C | 15-May-10 | Roche cobas | 402,570 IU/mL | HCV Ct Value - 16 | Innogenetics INNO-LIPA | 1a | Abbott PRISM | 7.38 S/Co | Anti-HCV | $40.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | Other Testing Results | Immunoblot C100(4+) C33(4+) C22(-) NS5(-) | |||||||||||||||||
| DLS13-05017 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 7.00 | $95.00 | 37 Y | M | Asian | < -70C | 28-Jun-13 | Roche cobas | 32,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Tenofovir 300 mg; Lopinavir / Ritonavir 200 mg / 50 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 25 U/L; AST: 25 U/L; Serum Creatinine: 103 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2006 | |||||||||||
| DLS13-05031 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 4.00 | $95.00 | 32 Y | M | Asian | < -70C | 09-Jul-13 | Roche cobas | 2,550,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional Testing | ALT: 131; AST: 83; Serum Creatinine: 63 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | |||||||||||
| DLS13-05032 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 10.00 | $95.00 | 36 Y | M | Asian | < -70C | 03-Sep-13 | Roche cobas | 1,810,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 38; AST: 26 | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2009 | |||||||||||
| DLS13-05033 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 13.00 | $95.00 | 28 Y | M | Asian | < -70C | 17-Sep-13 | Roche cobas | 36,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 78 U/L; AST: 44 U/L; Serum Creatinine: 66 umol/L | Hepatitis Serology | HBsAg+; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | |||||||||||
| DLS13-05034 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 17.00 | $95.00 | 31 Y | F | Asian | < -70C | 28-Aug-13 | Roche cobas | 842,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 237 U/L; AST: 168 U/L; Bilirubin: 20 umol/L; Serum Creatinine: 70 umol/L | Hepatitis Serology | HBsAg-; HIV- (ECLIA Cobas 6000) | |||||||||||||||
| DLS13-05036 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 14.00 | $95.00 | 62 Y | F | Asian | < -70C | 20-Jun-13 | Roche cobas | 17,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 140; AST: 39 | Hepatitis Serology | Anti HCV+ (Cobas 6000) / (Elisa) | |||||||||||||||
| DLS13-05037 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 13.00 | $95.00 | 30 Y | M | Asian | < -70C | 22-Aug-13 | Roche cobas | 13,100,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 22 U/L; AST: 25 U/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | |||||||||||
| DLS13-05038 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 12.00 | $95.00 | 40 Y | M | Asian | < -70C | 13-Sep-13 | Roche cobas | 73,500 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Nevirapine 200 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 36 U/L; AST: 40 U/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | |||||||||||
| DLS13-05041 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 5.00 | $95.00 | 32 Y | M | Asian | < -70C | 10-Jul-13 | Roche cobas | 60,700,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Fatigue; Abdominal pain; Joint pain | Additional Testing | ALT: 51; AST: 42; Serum Creatinine: 74 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2013 | |||||||||||
| DLS13-05044 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 12.00 | $95.00 | 44 Y | M | Asian | < -70C | 31-Jul-13 | Roche cobas | 17,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 175 U/L; AST: 74 U/L; Serum Creatinine: 105 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2008 | |||||||||||
| DLS13-05046 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 18.00 | $95.00 | 34 Y | M | Asian | < -70C | 12-Sep-13 | Roche cobas | 44,000,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 93 U/L; AST: 64 U/L | Co-Infections | HIV+ | 2013 | |||||||||||||
| DLS13-05047 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 6.00 | $95.00 | 31 Y | F | Asian | < -70C | 31-Jul-13 | Roche cobas | 3,220,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 26 U/L; AST: 34 U/L; Serum Creatinine: 65 umol/L | Hepatitis Serology | HBsAg+; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2007 | |||||||||||
| DLS13-05048 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 19.00 | $95.00 | 27 Y | M | Asian | < -70C | 05-Aug-13 | Roche cobas | 63,500,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg;Nevirapine 200 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 57 U/L; AST: 33 U/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2010 | |||||||||||
| DLS13-05049 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 37 Y | M | Asian | < -70C | 10-Sep-13 | Roche cobas | 11,700,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 118 U/L; AST: 64 U/L; Serum Creatinine: 88 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 1998 | |||||||||||
| DLS13-05055 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 39 Y | M | Asian | < -70C | 27-Jun-13 | Roche cobas | 7,170,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Sleep disturbances | Additional Testing | ALT: 106 U/L; AST: 61 U/L; Serum Creatinine: 83 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2006 | ||||||||||||
| DLS13-05056 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 37 Y | M | Asian | < -70C | 26-Jul-13 | Roche cobas | 10,800,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 72 U/L; AST: 48 U/L; Serum Creatinine: 91 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | |||||||||||
| DLS13-05058 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 1.00 | $95.00 | 34 Y | M | Asian | < -70C | 24-Jul-13 | Roche cobas | 21,800,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue; Jaundice; Weight loss | Additional Testing | ALT: 20; AST: 11; Bilirubin: 5.7 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2013 | |||||||||||
| DLS13-05059 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 2.00 | $95.00 | 42 Y | M | Asian | < -70C | 19-Jun-13 | Roche cobas | 31,500,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 67; AST: 97 | Hepatitis Serology | HBsAg-; Anti HCV+ | Co-Infections | HIV+ | 2012 | ||||||||||||
| DLS13-05066 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 40 Y | M | Asian | < -70C | 22-Jul-13 | Roche cobas | 16,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg;Nevirapine 200 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 47 U/L; AST: 24 U/L; Serum Creatinine: 76 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2007 | |||||||||||
| DLS13-05068 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 5.00 | $95.00 | 31 Y | M | Asian | < -70C | 14-Jun-13 | Roche cobas | 4,200,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 33; AST: 19; Bilirubin: 4.7 umol/L | |||||||||||||||||
| DLS13-05844 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 37 Y | M | Asian | < -70C | 13-Nov-13 | Roche cobas | 11,700,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice; Flu-like symptoms; Nausea | Additional Testing | ALT: 521 U/L; AST: 480 U/L; Bilirubin: 97.7 umol/L; Serum Creatinine: 93 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | |||||||||||||||
| DLS13-05847 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 50 Y | M | Asian | < -70C | 06-Dec-13 | Roche cobas | 9,870 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 220 U/L; AST: 82 U/L; ALP: 96 U/L; Bilirubin: 55 umol/L; Serum Creatinine: 89 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (ECLIA Cobas 6000) | |||||||||||||||
| DLS13-09599 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 5.00 | $95.00 | 47 Y | M | Asian | < -70C | 23-Dec-13 | Roche cobas | 50,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Decreased appetite; Fatigue; Diabetes | Additional Testing | ALT: 592 U/L; AST: 209 U/L; Bilirubin: 15 umol/L; Serum Creatinine: 71 umol/L | |||||||||||||||||
| DLS13-09601 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 18.00 | $95.00 | 37 Y | M | Asian | < -70C | 13-Nov-13 | Roche cobas | 1,570,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 213 U/L; AST: 84 U/L; Bilirubin: 78 umol/L; Serum Creatinine: 93 umol/L | Hepatitis Serology | HBsAg- (ECLIA Cobas 6000) | |||||||||||||||
| DLS13-09604 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 39 Y | M | Asian | < -70C | 22-Nov-13 | Roche cobas | 2,090,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 67 U/L; AST: 33 U/L; Serum Creatinine: 86 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2008 | |||||||||||
| DLS13-09607 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 7.00 | $95.00 | 37 Y | M | Asian | < -70C | 19-Dec-13 | Roche cobas | 58,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 98 U/L; AST: 48 U/L; Bilirubin: 7.7 umol/L; Serum Creatinine: 89 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (ECLIA Cobas 6000) | |||||||||||||||
| DLS13-09643 | Hepatitis C (HCV) Genotype 1 | Vietnam | Plasma | 1.00 | 7.00 | $95.00 | 36 Y | M | Asian | < -70C | 27-Dec-13 | Roche cobas | 19,100 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg;Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Asymptomatic | Additional Testing | ALT: 118 U/L; AST: 71 U/L; Serum Creatinine: 58 umol/L | Hepatitis Serology | HBsAg+; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2010 | |||||||||||
| DLS14-05319 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 56 Y | F | Asian | < -70C | 10-Jul-14 | Roche HCV Monitor | 1,150,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 199; AST: 241; Bilirubin: 11.3 umol/L; Serum Creatinine: 0.8 mg/dL | |||||||||||||||||
| DLS14-05321 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 43 Y | M | Asian | < -70C | 13-Jun-14 | Roche HCV Monitor | 2,600,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Abdominal pain; Sleep disturbances | Additional Testing | ALT: 114; AST: 132; Bilirubin: 65 umol/L; Serum Creatinine: 1.12 mg/dL | Hepatitis Serology | Anti HCV+ (Elisa) | Co-Infections | None | |||||||||||||
| DLS14-05333 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 19.00 | $95.00 | 54 Y | M | Asian | < -70C | 13-May-14 | Roche cobas | 9,320 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Depression | Additional Testing | ALT: 172; AST: 149; Bilirubin: 18.1 umol/L; Serum Creatinine: 0.77 mg/dL; ALP: 105 | |||||||||||||||||
| DLS14-05334 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 57 Y | F | Asian | < -70C | 12-May-14 | Roche cobas | 1,160 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Sleep disturbances | Additional Testing | ALT: 597; AST: 444; LDH: 294; Bilirubin: 199.6 umol/L; Serum Creatinine: 0.68 mg/dL | |||||||||||||||||
| DLS14-05336 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 63 Y | M | Asian | < -70C | 25-Mar-14 | Roche cobas | 705,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Depression | Additional Testing | ALT: 122 U/L; AST: 191 U/L | |||||||||||||||||
| DLS14-05340 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 62 Y | F | Asian | < -70C | 13-May-14 | Roche cobas | 1,300,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 113; AST: 119; ALP: 61; Bilirubin: 15.7 umol/L; Serum Creatinine: 0.8 mg/dL | |||||||||||||||||
| DLS14-05341 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 40 Y | M | Asian | < -70C | 16-Apr-14 | Roche cobas | 55,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 1435; AST: 2679; Bilirubin: 185.7 umol/L; Serum Creatinine: 1.0 mg/dL; Hepatitis C | |||||||||||||||||
| DLS14-05347 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 58 Y | M | Asian | < -70C | 19-Mar-14 | Roche cobas | 225,000 copies/mL | HCV | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Sleep disturbances | Additional Testing | ALT: 46; AST: 15; Bilirubin: 38.1 umol/L; Serum Creatinine: 1.0 mg/dL | Co-Infections | HBV+ | 2010 | |||||||||||||
| DLS14-05369 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 52 Y | F | Asian | < -70C | 10-Apr-14 | Roche cobas | 52,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 1102 U/L; AST: 1037 U/L; Bilirubin: 18 umol/L | |||||||||||||||||
| DLS14-05372 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 58 Y | F | Asian | < -70C | 13-Jun-14 | Eppendorf Real Time PCR | 6,250,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 282; AST: 478; Bilirubin: 43.3 umol/L; Serum Creatinine: 0.97 mg/dL | |||||||||||||||||
| DLS14-05373 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 64 Y | F | Asian | < -70C | 29-Apr-14 | Roche cobas | 1,920,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Abdominal pain; Jaundice | Additional Testing | ALT: 149; AST: 437; Bilirubin: 74.2 umol/L; Serum Creatinine: 58 umol/L | Hepatitis Serology | Anti HCV+ | Co-Infections | None | |||||||||||||
| DLS14-05377 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 59 Y | F | Asian | < -70C | 22-Jul-14 | Roche HCV Monitor | 4,960,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 104; AST: 52; Bilirubin: 11 umol/L; Serum Creatinine: 0.8 mg/dL | |||||||||||||||||
| DLS14-05379 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 33 Y | M | Asian | < -70C | 22-Apr-14 | Roche cobas | 9,020,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Sleep disturbances | |||||||||||||||||||
| DLS14-05381 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 37 Y | M | Asian | < -70C | 13-Jun-14 | Roche cobas | 10,600,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 71; AST: 52; Serum Creatinine: 92 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2003 | |||||||||||
| DLS14-05382 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 35 Y | M | Asian | < -70C | 12-Jun-14 | Roche cobas | 25,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 103; AST: 113 | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | |||||||||||
| DLS14-05385 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 67 Y | M | Asian | < -70C | 13-Jun-14 | Roche HCV Monitor | 1,510,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Abdominal pain; Sleep disturbances | Additional Testing | ALT: 66; AST: 103; ALP: 102; Bilirubin: 15.3 umol/L; Serum Creatinine: 0.67 mg/dL | Hepatitis Serology | Anti HCV+ (Elisa) | Co-Infections | None | |||||||||||||
| DLS14-05395 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 56 Y | F | Asian | < -70C | 13-May-14 | Roche cobas | 77,200,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Fatigue; Itching; Sleep disturbances | Additional Testing | ALT: 127; AST: 261; ALP: 88; Bilirubin: 14.3 umol/L; Serum Creatinine: 0.8 mg/dL | |||||||||||||||||
| DLS14-05396 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 39 Y | M | Asian | < -70C | 22-May-14 | Roche cobas | 452,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 156; AST: 20; Bilirubin: 8.3 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | |||||||||||
| DLS14-05410 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 52 Y | F | Asian | < -70C | 10-Jul-14 | Roche HCV Monitor | 2,850,000 IU/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 343; AST: 610; Bilirubin: 95.8 umol/L; Serum Creatinine: 0.66 mg/dL | |||||||||||||||||
| DLS14-05411 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 2.00 | $95.00 | 64 Y | F | Asian | < -70C | 06-May-14 | Roche cobas | 2,700,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Itching; Sleep disturbances; Depression | Additional Testing | ALT: 160; AST: 72; Serum Creatinine: 0.6 mg/dL | |||||||||||||||||
| DLS14-05413 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 45 Y | M | Asian | < -70C | 05-May-14 | Roche cobas | 1,810,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Abcarvir 300 mg Lamivudine 150 mg Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 51; AST: 66; Serum Creatinine: 131 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2002 | |||||||||||
| DLS14-05415 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 49 Y | M | Asian | < -70C | 21-May-14 | Roche cobas | 15,500,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 44; AST: 36; Serum Creatinine: 75 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2009 | |||||||||||
| DLS14-05416 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 32 Y | M | Asian | < -70C | 11-Jun-14 | Roche cobas | 2,140,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 58; AST: 49; Serum Creatinine: 94 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 1999 | |||||||||||
| DLS12-0197 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 6.00 | $95.00 | 32 Y | M | White | < -70C | 21-Nov-12 | Roche cobas | 3,280,000 IU/mL | 23-Aug-12 | Siemens TreGene HCV | 1a | 2006 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Abdominal Pain, Nausea | Additional Testing | ALT: 90; AST: 43; ALP: 172; Bilirubin: 0.44; Liver Disease Diagnosis: Chronic Hepatitis | 23-Aug-12 | Hepatitis Serology Result | anti HCV+ (Abbott) | 2006 | |||||||||||
| DLS12-8271 | Hepatitis C (HCV) Genotype 1 | USA | Plasma | 1.00 | 10.00 | $95.00 | 37 Y | M | Hispanic | < -70C | 12-Dec-12 | Roche cobas | 1,009,903 IU/mL | 11-Jun-12 | Genotype | 1 | 2005; Test Method Unvailable | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Pegylated Interferon; Ribavirin & Telaprevir | Acquired Infection Category | Surgery; Transfusion | Symptoms | Fatigue | Additional Testing | ALT: 50; AST: 32; ALP: 60; Bilirubin: 0.5; Serum Creatinine: 0.92 mg/dL; Biopsy: S2 (Jan-2005); Liver Disease Diagnosis: G1 S0 | 7-Jun-12; Jan-2012 | Hepatitis Serology Result | HCV RNA PCR Pos (11-Jun-2012); HCV RNA PCR Pos (23-Feb-2012); HCV RNA PCR Neg (19-Jan-2012); HCV RNA PCR Neg (12-Jan-2012) | |||||||||||
| DLS13-02034 | Hepatitis C (HCV) Genotype 1 | USA | Serum | 1.00 | 9.00 | $95.00 | 66 Y | M | White | < -70C | 09-Apr-13 | Test Method Unavailable | 860,881 IU/mL | 1-Sep-12 | Genotype | 1b | Test Method Unavailable | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased Appetite; Fatigue; Itching | Additional Testing | ALT: 255; AST: 165; ALP: 73; LDH: 165; Bilirubin: 11.2; Serum Creatinine: 0.9 mg/dL; (Biopsy: G2 S2 Jan-2008) | 15-Aug-12 | ||||||||||||||
| DLS12-6289 | Hepatitis C (HCV) Genotype 1 | Germany | Plasma | 1.00 | 13.00 | $95.00 | 77 Y | F | White | < -70C | 11-Nov-14 | Roche cobas | 1,000,000 IU/mL | 11-Sep-14 | Sequencing In-house Assay | 1b | 11-Sep-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | N/A | Additional Testing | ALT: 44.8; AST: 40.8; ALP: 55; LDH: 273; Bilirubin: 1.7 mg/dL; Serum Creatinine: 0.69 mg/dL | 11-Sep-14 | ||||||||||||||
| DLS14-05328 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 7.00 | $95.00 | 36 Y | M | Asian | < -70C | 20-Jul-14 | Roche cobas | 3,360,000 IU/mL | 16-Jul-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 16-Jul-2014 | ||||||||||||||
| DLS14-05339 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 36 Y | M | Asian | < -70C | 10-Sep-14 | Roche cobas | 67,900 IU/mL | 5-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 44; AST: 116; Bilirubin: 7.2 umol/L; Serum Creatinine: 1.1 mg/dL | 28-Aug-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05342 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.75 | $95.00 | 26 Y | M | Asian | < -70C | 15-Aug-14 | Roche cobas | 1,170,000 IU/mL | 15-Aug-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Hepatitis Serology Result | ||||||||||||||||
| DLS14-05352 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 54 Y | F | Asian | < -70C | 01-Aug-14 | Roche cobas | 96,000 copies/mL | 16-Jul-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Abdominal pain | Additional Testing | ALT: 254; AST: 583 | 16-Jul-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05359 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 44 Y | M | Asian | < -70C | 08-Sep-14 | Roche cobas | 900,000 IU/mL | 5-Sep-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 53; AST: 18; Bilirubin: 5.6 umol/L; Serum Creatinine: 1.08 mg/dL | 28-Aug-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05361 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 45 Y | M | Asian | < -70C | 03-Oct-14 | Roche cobas | 4,020,000 copies/mL | 17-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Nevirapine 200 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 1046; AST: 647; | 11-Sep-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 27-Sep-10; 5-Oct-2010 | Co-Infections | HIV+ | 27-Sep-10 | |||||||
| DLS14-05365 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 35 Y | M | Asian | < -70C | 06-Oct-14 | Roche cobas | 11,500 copies/mL | 4-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 181; AST: 129; Serum Creatinine: 92 umol/L | 4-Jun-14 | Hepatitis Serology Result | Co-Infections | HIV+ | 18-Apr-14 | |||||||||
| DLS14-05370 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 41 Y | M | Asian | < -70C | 30-Jun-14 | Roche cobas | 1,750,000 copies/mL | 26-Jun-14 | Real-Time PCR | 1 | 7-Jul-14 | $95.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 77; AST: 74; Serum Creatinine: 105 umol/L | 27-May-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 27-May-2014 | Co-Infections | HIV+ | 16-May-14 | |||||||
| DLS14-05374 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 5.00 | $95.00 | 31 Y | M | Asian | < -70C | 18-Aug-14 | Roche cobas | 7,070 IU/mL | 21-May-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 20; AST: 30; Serum Creatinine: 1.08 mg/dL | 13-May-14 | Hepatitis Serology Result | Anti HCV + | 13-May-2014 | |||||||||||
| DLS14-05383 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 43 Y | M | Asian | < -70C | 14-May-14 | Roche cobas | 12,700 copies/mL | 6-May-14 | Real-Time PCR | 1 | 22-May-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 52; AST: 51; Serum Creatinine: 98 umol/L | 3-Apr-14 | Hepatitis Serology Result | HBsAg +; Anti HCV + (Elisa) | 2-Apr-2013 | Co-Infections | HIV+ | 2-Apr-13 | |||||||
| DLS14-05390 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 49 Y | F | Asian | < -70C | 24-Sep-14 | Roche cobas | 1,800,000 IU/mL | 17-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 176; AST: 162; Bilirubin: 15.3 umol/L; Serum Creatinine: 0.7 mg/dL | 22-Sep-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05391 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 41 Y | M | Asian | < -70C | 31-Jul-14 | Roche cobas | 53,300 IU/mL | 25-Jun-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Hepatitis Serology Result | HBsAg +; Anti HCV + (Elisa) | 20-Jun-2014 | ||||||||||||||
| DLS14-05394 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 58 Y | F | Asian | < -70C | 29-Jul-14 | Roche cobas | 4,200,000 copies/mL | 18-Jul-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional Testing | ALT: 54; AST: 60; ALP: 61; Bilirubin: 10 umol/L; Serum Creatinine: 67 umol/L | 12-Jul-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05398 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 27 Y | M | Asian | < -70C | 15-Jul-14 | Roche cobas | 1,700 IU/mL | 13-Jun-14 | Real-Time PCR | 1 | 18-Jul-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 143; AST: 37; Serum Creatinine: 96 umol/L | 9-Jul-14 | Hepatitis Serology Result | HBsAg - (Elisa) | 15-Jun-2014 | |||||||||||
| DLS14-05399 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 40 Y | M | Asian | < -70C | 20-Aug-14 | Roche cobas | 27,400 IU/mL | 15-Aug-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Nausea | Additional Testing | ALT: 47; AST: 37 | 6-Aug-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05400 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 33 Y | F | Asian | < -70C | 18-Aug-14 | Roche cobas | 441,000 IU/mL | 7-Aug-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 21; AST: 23; Bilirubin: 8.1 umol/L; Serum Creatinine: 0.67 mg/dL | 7-Aug-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-05404 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 45 Y | M | Asian | < -70C | 02-Oct-14 | Roche cobas | 13,700,000 copies/mL | 11-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Abdominal pain | Additional Testing | ALT: 44; AST: 81 | 3-Sep-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 10-Jan-2007 | Co-Infections | HIV+ | 15-Jun-06 | |||||||
| DLS14-05412 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 37 Y | F | Asian | < -70C | 25-Aug-14 | Roche cobas | 2,900 IU/mL | 19-Aug-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 19; AST: 14 | 19-Aug-14 | Hepatitis Serology Result | Anti HCV + (Elisa) | 28-Aug-2014 | |||||||||||
| DLS14-07965 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 64 Y | M | Asian | < -70C | 25-Sep-14 | Roche cobas | 17,300 IU/mL | 24-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 77 U/L; AST: 58 U/L; Bilirubin: 7.8 umol/L; Serum Creatinine: 1.0 mg/dL | 10-Sep-14 | ||||||||||||||
| DLS14-07966 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 35 Y | M | Asian | < -70C | 13-Oct-14 | Roche cobas | 40,800 IU/mL | 25-Sep-14 | Real-Time PCR | 1 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 61 U/L; AST: 78 U/L; Bilirubin: 9.8 umol/L; Serum Creatinine: 0.9 mg/dL | 3-Oct-14 | ||||||||||||||
| DLS14-08034 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 41 Y | M | Asian | < -70C | 05-Nov-14 | Roche cobas | 187,000 copies/mL | 10-Jul-14 | Real-Time PCR | 1 | 14-Nov-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional Testing | ALT: 97 U/L; AST: 122 U/L; Serum Creatinine: 66 umol/L | 7-Jun-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 20-Jun-2010 | |||||||||||
| DLS14-08040 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 53 Y | F | Asian | < -70C | 28-Oct-14 | Roche cobas | 131,000 IU/mL | 14-Oct-14 | Real-Time PCR | 1 | 29-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue; Itching | Additional Testing | ALT: 274 U/L; AST: 223 U/L | 14-Oct-14 | Hepatitis Serology Result | Anti HCV + (Elisa) | 14-Oct-2014 | |||||||||||
| DLS14-08044 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 35 Y | M | Asian | < -70C | 07-Nov-14 | Roche cobas | 51,200,000 copies/mL | 26-Aug-14 | Real-Time PCR | 1 | 14-Nov-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 69 U/L; AST: 47 U/L | 21-Aug-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 21-Aug-2014 | Co-Infections | HIV + | 1-Jul-03 | |||||||
| DLS14-08046 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 35 Y | M | Asian | < -70C | 10-Nov-14 | Roche cobas | 3,550,000 copies/mL | 10-Sep-14 | Real-Time PCR | 1 | 14-Nov-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 48 U/L; AST: 69 U/L | 20-Aug-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 17-Jul-2013; 30-Jul-2013 | Co-Infections | HIV + | 17-Jul-13 | |||||||
| DLS14-08052 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 38 Y | M | Asian | < -70C | 24-Sep-14 | Roche cobas | 6,220,000 IU/mL | 16-Sep-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 49 U/L; AST: 85 U/L; Bilirubin: 8.0 umol/L; Serum Creatinine: 1.0 mg/dL | 11-Sep-14 | ||||||||||||||
| DLS14-07962 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 31 Y | M | Asian | < -70C | 13-Jan-15 | Roche cobas | 5,920,000 copies/mL | 6-Jan-15 | Real-Time PCR | 1 | 21-Jan-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 89 U/L; AST: 38 U/L; Serum Creatinine: 89 umol/L | 6-Jan-15 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 6-Jan-2015 | Co-Infections | |||||||||
| DLS14-07974 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 37 Y | M | Asian | < -70C | 03-Dec-14 | Roche cobas | 712,000 copies/mL | 30-Oct-14 | Real-Time PCR | 1 | 4-Dec-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | Unknown | Symptoms | Decreased Appetite; Fatigue | Additional Testing | ALT: 30 U/L; AST: 100 U/L; Serum Creatinine: 99 umol/L | 26-Jun-14 | Hepatitis Serology Result | HBsAG -; Anti HCV + (Elisa) | 6-Dec-2012 | ||||||||||
| DLS14-08045 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 44 Y | M | Asian | < -70C | 11-Dec-14 | Roche cobas | 1,000,000 copies/mL | 27-Nov-14 | Real-Time PCR | 1 | 16-Dec-14 | $95.00 | 3-series HepB Vaccine | no | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Itching | Additional Testing | ALT: 37 U/L; AST: 124 U/L; Serum Creatinine: 62 umol/dL | 27-Nov-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 14-May-2008 | Co-Infections | HIV Positive | 1-Jul-08 | |||||||
| DLS14-08047 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 65 Y | M | Asian | < -70C | 29-Jan-15 | Roche cobas | 75,600 IU/mL | 23-Jan-15 | Real-Time PCR | 1 | 4-Feb-15 | $95.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 150 U/L; AST: 120 U/L; Bilirubin: 20.5 umol/L; Serum Creatinine: 85 umol/dL | 20-Jan-15 | Hepatitis Serology Result | None | |||||||||||
| DLS14-08055 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 39 Y | M | Asian | < -70C | 15-Jan-15 | Roche cobas | 5,050,000 copies/mL | 3-Dec-14 | Real-Time PCR | 1 | 22-Jan-15 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Joint pain; Sleep Disturbances | Additional Testing | ALT: 101 U/L; AST: 110 U/L; Serum Creatinine: 74 umol/L | 17-Nov-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 4-Aug-2011 | Co-Infections | HIV Positive | 1-Jul-01 | |||||||
| DLS14-07976 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 4.00 | $95.00 | 48 Y | M | Asian | <-70C | 02-Apr-15 | Roche cobas | 69,000,000 IU/mL | 27-Mar-15 | Real-Time PCR | 1 | 8-Apr-15 | $95.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 827 U/L; AST: 320 U/L; Bilirubin: 299 umol/L; Serum Creatinine: 79 umol/L | 31-Mar-15 | Hepatitis Serology Result | None | ||||||||||||
| DLS14-08004 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 38 Y | M | Asian | <-70C | 02-Mar-15 | Roche cobas | 82,500 copies/mL | 5-Nov-14 | Real-Time PCR | 1 | 13-Mar-15 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Abdominal Pain | Additional Testing | ALT: 66 U/L; AST: 87 U/L | 27-Oct-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 15-Mar-11 | |||||||||||
| DLS14-08025 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 37 Y | M | Asian | <-70C | 13-May-15 | Roche cobas | 4,900 copies/mL | 28-Jan-15 | Real-Time PCR | 1 | 13-Mar-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 25 U/L; AST: 90 U/L; Serum Creatinine: 99 umol/L | 14-Aug-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 20-Jan-14 | |||||||||||
| DLS14-07981 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 41 Y | M | Asian | <-70C | 14-May-15 | Roche cobas | 888,000 IU/mL | 6-Mar-15 | Real-Time PCR | 1 | 21-May-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | No symptoms | |||||||||||||||||
| DLS14-08017 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 35 Y | M | Asian | <-70C | 27-May-15 | Roche cobas | 1,940,000 copies/mL | 23-Apr-15 | Real-Time PCR | 1 | 9-Jul-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg, Lamivudine 150 mg, Efavirenz 600 mg | Acquired Infection Category | Sexual transmission , IV Drug Abuse | Symptoms | No symptoms | ||||||||||||||||
| DLS14-08028 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 5.00 | $95.00 | 40 Y | M | Asian | <-70C | 12-Aug-15 | Roche cobas | 52,000,000 copies/mL | 5-May-15 | Real-Time PCR | 1 | 20-Aug-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | No symptoms | |||||||||||||||||
| DLS14-08029 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 56 Y | M | Asian | <-70C | 21-Jul-15 | Roche cobas | 3,900,000 IU/mL | 16-Jul-15 | Real-Time PCR | 1 | 7-Aug-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | |||||||||||||||||
| DLS14-21184 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 38 Y | M | Asian | <-70C | 28-Aug-15 | Roche cobas | 15,200,000 IU/mL | 13-Aug-15 | Real-Time PCR | 1 | 3-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite | |||||||||||||||||
| DLS14-21223 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 29 Y | M | Asian | <-70C | 01-Sep-15 | Roche cobas | 11,300,000 IU/mL | 20-Aug-15 | Real-Time PCR | 1 | 3-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | |||||||||||||||||
| DLS14-21235 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 43 Y | F | Asian | <-70C | 18-Aug-15 | Roche cobas | 16,700,000 IU/mL | 6-Aug-15 | Real-Time PCR | 1 | 20-Aug-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Nausea | |||||||||||||||||
| DLS14-21236 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 57 Y | F | Asian | <-70C | 01-Sep-15 | Roche cobas | 14,900,000 IU/mL | 19-Aug-15 | Real-Time PCR | 1 | 3-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | |||||||||||||||||
| DLS14-21243 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 61 Y | F | Asian | <-70C | 21-Jul-15 | Roche cobas | 5,690,000 IU/mL | 16-Jul-15 | Real-Time PCR | 1 | 7-Aug-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue | |||||||||||||||||
| DLS14-21245 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 65 Y | F | Asian | <-70C | 08-Sep-15 | Roche cobas | 8,950,000 IU/mL | 4-Sep-15 | Real-Time PCR | 1 | 10-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | |||||||||||||||||
| DLS14-21248 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 36 Y | M | Asian | <-70C | 07-Sep-15 | Roche cobas | 9,000,000 copies/mL | 3-Jul-15 | Real-Time PCR | 1 | 10-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | |||||||||||||||||
| DLS14-21260 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 56 Y | M | Asian | <-70C | 07-Sep-15 | Roche cobas | 5,990 copies/mL | 1-Sep-15 | Real-Time PCR | 1 | 10-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue | |||||||||||||||||
| DLS14-21276 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 31 Y | M | Asian | <-70C | 08-Sep-15 | Roche cobas | 695,000 IU/mL | 4-Sep-15 | Real-Time PCR | 1 | 10-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | |||||||||||||||||
| DLS14-21187 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 20 Y | M | Asian | <-70C | 17-Sep-15 | Real-Time PCR | 1 | 18-Sep-15 | $95.00 | Signs and Symptoms | Decreased appetite | ||||||||||||||||||||||||||
| DLS14-21189 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 38 Y | M | Asian | <-70C | 30-Sep-15 | Real-Time PCR | 1 | 1-Oct-15 | $95.00 | Signs and Symptoms | No symptoms | ||||||||||||||||||||||||||
| DLS14-21198 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 39 Y | M | Asian | <-70C | 04-Nov-15 | Real-Time PCR | 1 | 11-Nov-15 | $95.00 | Signs and Symptoms | Fatigue; Nausea; GI bleeding | ||||||||||||||||||||||||||
| DLS14-21204 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 69 Y | F | Asian | <-70C | 01-Oct-15 | Roche cobas | 1,680,000 IU/mL | 30-Sep-15 | Real-Time PCR | 1 | 8-Oct-15 | $95.00 | Signs and Symptoms | Decreased appetite; Fatigue | |||||||||||||||||||||||
| DLS14-21216 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 33 Y | M | Asian | <-70C | 15-Dec-15 | Real-Time PCR | 1 | 16-Dec-15 | $95.00 | Signs and Symptoms | No symptoms | Co-Infections | HIV Positive | 13-Oct-15 | |||||||||||||||||||||||
| DLS14-21224 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 43 Y | M | Asian | <-70C | 26-Oct-15 | Roche cobas | 5,720,000 IU/mL | 9-Oct-15 | Real-Time PCR | 1 | 5-Nov-15 | $95.00 | Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | HIV Positive | 8-Feb-10 | ||||||||||||||||||||
| DLS14-21230 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 7.00 | $95.00 | 66 Y | M | Asian | <-70C | 09-Dec-15 | Roche cobas | 1,820,000 IU/mL | 3-Dec-15 | Real-Time PCR | 1 | 16-Dec-15 | $95.00 | Signs and Symptoms | Fatigue; Abdominal pain | |||||||||||||||||||||||
| DLS14-21250 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 25 Y | M | Asian | <-70C | 16-Oct-15 | Roche cobas | 412,000 IU/mL | 28-Sep-15 | Real-Time PCR | 1 | 19-Nov-15 | $95.00 | Signs and Symptoms | No symptoms | Co-Infections | HIV Positive | 18-Apr-14 | ||||||||||||||||||||
| DLS14-21262 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 29 Y | M | Asian | <-70C | 18-Sep-15 | Real-Time PCR | 1 | 24-Sep-15 | $95.00 | Signs and Symptoms | No symptoms | Co-Infections | HIV Positive | 5-Jul-13 | |||||||||||||||||||||||
| DLS14-21275 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 51 Y | M | Asian | <-70C | 06-Oct-15 | Roche cobas | 5,890,000 IU/mL | 24-Sep-15 | Real-Time PCR | 1 | 8-Oct-15 | $95.00 | Signs and Symptoms | Fatigue | |||||||||||||||||||||||
| DLS14-21280 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 57 Y | F | Asian | <-70C | 02-Oct-15 | Real-Time PCR | 1 | 8-Oct-15 | $95.00 | Signs and Symptoms | Fatigue; Fever; Cough | ||||||||||||||||||||||||||
| DLS14-21282 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 70 Y | F | Asian | <-70C | 10-Sep-15 | Roche cobas | 11,720,000 IU/mL | 8-Sep-15 | Real-Time PCR | 1 | 17-Sep-15 | $95.00 | Signs and Symptoms | Fatigue; Nausea | |||||||||||||||||||||||
| DLS16-67368 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 57 Y | M | Asian | <-70C | 07-Nov-16 | Roche cobas | 7,230,000 IU/mL | 4-Nov-16 | Real-Time PCR | 1 | 9-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 309 U/L; AST: 931 U/L; Bilirubin: 15.5 umol/L; Serum Creatinine: 95 umol/L | 2-Nov-16 | Hepatitis Serology | HCV Ab + (Architect plus cobas) | 28-Oct-16 | Co-Infections | N/A | |||||||||
| DLS16-67372 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 40 Y | F | Asian | <-70C | 29-Sep-16 | Roche cobas | 1,880,000 IU/mL | 28-Sep-16 | Real-Time PCR | 1 | 3-Oct-16 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite | Additional Testing | ALT: 143 U/L; AST: 176 U/L; Bilirubin: 13.8 umol/L; Serum Creatinine: 72 umol/L | 22-Sep-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67374 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 19.00 | $95.00 | 33 Y | M | Asian | <-70C | 27-Sep-16 | Roche cobas | 338,000 IU/mL | 23-Sep-16 | Real-Time PCR | 1 | 29-Sep-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Decreased appetite; Fatigue; Itching | Additional Testing | ALT: 76 U/L; AST: 345 U/L; Bilirubin: 10.2 umol/L; Serum Creatinine: 1153 umol/L | 20-Sep-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67403 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 35 Y | M | Asian | <-70C | 01-Nov-16 | Roche cobas | 837,000 IU/mL | 26-Oct-16 | Real-Time PCR | 1 | 3-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 186 U/L; AST: 602 U/L; Bilirubin: 82.5 umol/L; Serum Creatinine: 74 umol/L | 31-Oct-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | Oct-16 | Co-Infections | N/A | |||||||||
| DLS16-67411 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 54 Y | F | Asian | <-70C | 25-Oct-16 | Roche cobas | 195,000 IU/mL | 24-Oct-16 | Real-Time PCR | 1 | 29-Oct-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Abdominal pain; Itching | Additional Testing | ALT: 84 U/L; AST: 168 U/L; Bilirubin: 16.2 umol/L; Serum Creatinine: 74 umol/L | 5-Oct-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | 5-Oct-16 | Co-Infections | N/A | |||||||||
| DLS16-67432 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 48 Y | F | Asian | <-70C | 13-Oct-16 | Roche cobas | 9,800 IU/mL | 11-Oct-16 | Real-Time PCR | 1 | 17-Oct-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 34 U/L; AST: 47 U/L; Bilirubin: 12.1 umol/L; Serum Creatinine: 68 umol/L | 6-Oct-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67434 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 17.00 | $95.00 | 42 Y | M | Asian | <-70C | 23-Sep-16 | Roche cobas | 6,800 IU/mL | 23-Sep-16 | Real-Time PCR | 1 | 29-Sep-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 166 U/L; AST: 276 U/L; Bilirubin: 55.1 umol/L; Serum Creatinine: 77 umol/L | 21-Sep-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | 2006 | |||||||||
| DLS16-67437 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 40 Y | M | Asian | <-70C | 06-Oct-16 | Roche cobas | 1,460,000 IU/mL | 4-Oct-16 | Real-Time PCR | 1 | 10-Oct-16 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 39 U/L; AST: 86 U/L; Serum Creatinine: 76 umol/L | 28-Sep-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67454 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 20.00 | $95.00 | 61 Y | M | Asian | <-70C | 27-Sep-16 | Roche cobas | 217,000 IU/mL | 26-Sep-16 | Real-Time PCR | 1 | 29-Sep-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 45 U/L; AST: 5 U/L; 42621; Serum Creatinine: 172 umol/L | 23-Sep-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67457 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 43 Y | M | Asian | <-70C | 13-Oct-16 | Roche cobas | 178,000 IU/mL | 11-Oct-16 | Real-Time PCR | 1 | 17-Oct-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 121 U/L; AST: 133 U/L; Bilirubin: 9.4 umol/L; Serum Creatinine: 97 umol/L | 6-Oct-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67460 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 44 Y | F | Asian | <-70C | 08-Nov-16 | Roche cobas | 21,200 IU/mL | 2-Nov-16 | Real-Time PCR | 1 | 10-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 41 U/L; AST: 65 U/L; Bilirubin: 11.5 umol/L; Serum Creatinine: 63 umol/L | 28-Oct-16 | Hepatitis Serology | N/A | Co-Infections | N/A | ||||||||||
| DLS16-67465 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 30 Y | M | Asian | <-70C | 21-Nov-16 | Roche HCV Monitor | 11,300,000 copies/mL | 15-Nov-16 | Real-Time PCR | 1 | 22-Nov-16 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | Sexual transmission | Symptoms | No symptoms | Additional Testing | ALT: 68 U/L; AST: 110 U/L; Serum Creatinine: 90 umol/L | 13-Oct-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | 12-Apr-16 | ||||||||
| DLS16-67476 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 58 Y | M | Asian | <-70C | 30-Nov-16 | Roche cobas | 270,000 IU/mL | 28-Nov-16 | Real-Time PCR | 1 | 1-Dec-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Abdominal pain | Additional Testing | ALT: 85 U/L; AST: 88 U/L; Bilirubin: 49.2 umol/L; Serum Creatinine: 83 umol/L | 27-Nov-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | 21-Nov-16 | Co-Infections | N/A | |||||||||
| DLS16-67500 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 34 Y | M | Asian | <-70C | 14-Nov-16 | Roche HCV Monitor | 44,000,000 copies/mL | 25-Nov-16 | Real-Time PCR | 1 | 16-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 14 U/L; AST: 29 U/L; Serum Creatinine: 87 umol/L | 13-Oct-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | 13-Oct-15 | |||||||||
| DLS16-67502 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 43 Y | M | Asian | <-70C | 21-Nov-16 | Roche cobas | 7,710,000 copies/mL | 20-Nov-16 | Real-Time PCR | 1 | 22-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 71 U/L; AST: 55 U/L; Serum Creatinine: 92 umol/L | 19-May-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | 10-Aug-10 | ||||||||
| DLS16-67578 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 41 Y | F | Asian | <-70C | 29-Nov-16 | Roche cobas | 2,160,000 IU/mL | 24-Nov-16 | Real-Time PCR | 1 | 1-Dec-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 117 U/L; AST: 251 U/L; Bilirubin: 15.4 umol/L; Serum Creatinine: 61 umol/L | 25-Nov-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | 21-Nov-16 | Co-Infections | N/A | |||||||||
| DLS16-67659 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 38 Y | M | Asian | <-70C | 15-Nov-16 | Roche HCV Monitor | 2,060,000 copies/mL | 13-Nov-16 | Real-Time PCR | 1 | 16-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 111 U/L; AST: 65 U/L; Serum Creatinine: 82 umol/L; Biopsy Result: (F1 (6 kPa); 25-Dec-2014) | 14-Sep-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | 31-Dec-14 | |||||||||
| DLS16-67785 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 35 Y | M | Asian | <-70C | 17-Nov-16 | Roche HCV Monitor | 2,990,000 copies/mL | 15-Nov-16 | Real-Time PCR | 1 | 18-Nov-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 59 U/L; AST: 57 U/L; Serum Creatinine: 94 umol/L; Biopsy Result: (F1; 8-Mar-2016) | 13-Sep-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | 10-Feb-16 | |||||||||
| DLS16-67471 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 40 Y | M | Asian | <-70C | 18-Jan-17 | Roche Cobas | 10,400,000 IU/mL | 16-Jan-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional Testing | ALT: 54 U/L, AST: 27 U/L, Bilirubin: 62 umol/L, Serum Creatinine: 74 umol/L | 17-Jan-2017 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67490 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 39 Y | F | Asian | <-70C | 14-Mar-17 | Roche Cobas | 7,640,000 IU/mL | 10-Mar-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 535 U/L, AST: 1173 U/L, Bilirubin: 53.4 umol/L, Serum Creatinine: 70 umol/L, HCV 2017 | 13-Mar-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | None | ||||||||||||
| DLS16-67505 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 38 Y | M | Asian | <-70C | 12-Jan-17 | Roche Cobas | 1,560,000 copies/mL | 10-Jan-17 | $95.00 | 3-Series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 47 U/L, AST: 157 U/L, Serum Creatinine: 87 umol/L | 27-Sep-2016 | Hepatitis Serology | None | Co-Infections | HIV+ | 9-Oct-10 | |||||||||||
| DLS16-67506 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 43 Y | F | Asian | <-70C | 30-Dec-16 | Roche Cobas | 83,700 IU/mL | 29-Dec-16 | $95.00 | 3-Series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Abdominal pain | Additional Testing | ALT: 89 U/L, AST: 123 U/L, Bilirubin: 17.3 umol/L, Serum Creatinine: 74 umol/L, HCV 2014 | 22-Dec-2016 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67537 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 28 Y | M | Asian | <-70C | 07-Feb-17 | Roche Cobas | 21,100,000 IU/mL | 5-Feb-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue; Abdominal pain | Additional Testing | ALT: 128 U/L, AST: 138 U/L, Bilirubin: 21.4 umol/L, Serum Creatinine: 54 umol/L, HCV 2017 | 5-Feb-2017 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67539 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 44 Y | M | Asian | <-70C | 08-Mar-17 | Roche Cobas | 2,060,000 copies/mL | 6-Mar-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue | Additional Testing | ALT: 69 U/L, AST: 120 U/L , Serum Creatinine: 103 umol/L | 26-Dec-2016 | Hepatitis Serology | None | Co-Infections | HIV+ | 12-Nov-12 | |||||||||||
| DLS16-67587 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 39 Y | F | Asian | <-70C | 01-Dec-16 | Roche Cobas | 4,450,000 IU/mL | 29-Nov-16 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue | Additional Testing | ALT: 37 U/L, AST: 29 U/L, Serum Creatinine: 62 umol/L | 24-Nov-2016 | Hepatitis Serology | None | Co-Infections | HIV+ | 19-Mar-14 | |||||||||||
| DLS16-67588 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 75 Y | M | Asian | <-70C | 11-Jan-17 | Roche Cobas | 13,800 copies/mL | 9-Jan-17 | $95.00 | 3-Series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional Testing | ALT: 110 U/L, AST: 90 U/L | 4-Jan-2017 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67597 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 49 Y | F | Asian | <-70C | 02-Mar-17 | Roche Cobas | 2,100,000 IU/mL | 1-Mar-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 206 U/L, AST: 260 U/L, Serum Creatinine: 97 umol/LHCV, 2017 | 27-Feb-2017 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67600 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 58 Y | M | Asian | <-70C | 05-Dec-16 | Roche Cobas | 95,000 IU/mL | 4-Dec-16 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue | Additional Testing | ALT: 120 U/L, AST: 81 U/L | 23-Nov-2016 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67602 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 33 Y | F | Asian | <-70C | 27-Dec-16 | Roche Cobas | 436,000 copies/mL | 26-Dec-16 | $95.00 | 3-Series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue | Additional Testing | ALT: 102 U/L, AST: 61 U/L, Serum Creatinine: 62 umol/L | 15-Dec-2016 | Hepatitis Serology | None | Co-Infections | HIV+ | 4-Dec-13 | |||||||||||
| DLS16-67604 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 34 Y | F | Asian | <-70C | 29-Mar-17 | Roche Cobas | 8,260,000 IU/mL | 27-Mar-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue; Abdominal pain | Additional Testing | ALT: 46 U/L, AST: 51 U/L, Bilirubin: 17.6 umol/L, Serum Creatinine: 63 umol/L, Chronic HCV 2010 | 20-Mar-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | AIDS+ | 2010 | |||||||||||
| DLS16-67620 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 37 Y | M | Asian | <-70C | 22-Dec-16 | Roche Cobas | 210,000 IU/mL | 21-Dec-16 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Abdominal pain | Additional Testing | ALT: 43 U/, LAST: 24 U/L, Serum Creatinine: 87 umol/L, HCV 2010 | 20-Dec-2016 | Hepatitis Serology | None | Co-Infections | HIV+ | 19-Aug-10 | |||||||||||
| DLS16-67622 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 67 Y | M | Asian | <-70C | 09-Dec-16 | Roche Cobas | 162,000 IU/mL | 8-Dec-16 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 72 U/L, AST: 84 U/L, Bilirubin: 19 umol/L, Serum Creatinine: 63 umol/L, Chronic HCV 2015 | 6-Dec-2016 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67627 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 41 Y | M | Asian | <-70C | 20-Feb-17 | Roche Cobas | 23,000,000 IU/mL | 18-Feb-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 32.8 U/L, AST: 24.2 U/L, Serum Creatinine: 77.2 umol/L, Chronic HCV 2015 | 7-Feb-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | None | ||||||||||||
| DLS16-67632 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 52 Y | M | Asian | <-70C | 16-Dec-16 | Roche Cobas | 170,000 IU/mL | 15-Dec-16 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional Testing | ALT: 82 U/L, AST: 63 U/L, Chronic HCV 2015 | 15-Dec-2016 | Hepatitis Serology | None | Co-Infections | None | ||||||||||||
| DLS16-67642 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 13.00 | $95.00 | 42 Y | M | Asian | <-70C | 08-Dec-16 | Roche Cobas | 30,600,000 copies/mL | 6-Dec-16 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue | Additional Testing | ALT: 12 U/L, AST: 46 U/L, Serum Creatinine: 128 umol/L | 26-Sep-2016 | Hepatitis Serology | None | Co-Infections | HIV+ | 15-Oct-10 | |||||||||||
| DLS16-67649 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 34 Y | M | Asian | <-70C | 23-Feb-17 | Roche Cobas | 910,000 IU/mL | 21-Feb-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 61 U/L, AST: 41 U/L, Bilirubin: 45 umol/L, Serum Creatinine: 74 umol/L, Chronic HCV 2014 | 20-Feb-2017 | Hepatitis Serology | None | Co-Infections | HIV+ | 17-Jul-14 | |||||||||||
| DLS16-67653 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 46 Y | F | Asian | <-70C | 12-Apr-17 | Roche Cobas | 26,000,000 IU/mL | 12-Apr-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Jaundice; Fatigue; Abdominal pain | Additional Testing | ALT: 1276 U/L, AST: 98 U/L, Bilirubin: 127 umol/L, Serum Creatinine: 82 umol/L, HCV 9-Apr-2017 | 10-Apr-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | None | ||||||||||||
| DLS16-67782 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 48 Y | M | Asian | <-70C | 05-Apr-17 | Roche Cobas | 590,000 IU/mL | 2-Apr-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Depression; Fatigue; Jaundice | Additional Testing | ALT: 101 U/LAST: 173 U/L Bilirubin: 12.6 umol/LSerum Creatinine: 89 umol/LChronic HCV Mar-2017 | 29-Mar-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | None | ||||||||||||
| DLS16-67509 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 15.00 | $95.00 | 57 Y | M | Asian | <-70C | 26-Apr-17 | Roche Cobas | 736,000 IU/mL | 26-Apr-17 | Real Time PCR | 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 72 U/L | AST: 64 U/L | Bilirubin: 62 umol/L | Serum Creatinine: 54 umol/L | 25-Apr-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | 3-Jul-1905 | Co-Infections | None | |||||||||
| DLS16-67507 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 57 Y | M | Asian | <-70C | 27-Apr-17 | Roche Cobas | 6,690 IU/mL | 27-Apr-17 | Real Time PCR | 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 91 U/L | AST: 90 U/L | Bilirubin: 22 umol/L | Serum Creatinine: 73 umol/L | 26-Apr-17 | Hepatitis Serology | None | Co-Infections | None | ||||||||||
| DLS16-67508 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 35 Y | M | Asian | <-70C | 27-Apr-17 | Roche Cobas | 2,050,000 IU/mL | 27-Apr-17 | Real Time PCR | 1 | 28-Apr-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | IV Drug Abuse | Symptoms | Itching; Unexplained weight loss; Fatigue | Additional Testing | ALT: 32 U/L | AST: 45 U/L | Bilirubin: 21 umol/L | Serum Creatinine: 73 umol/L | 22-Apr-17 | Hepatitis Serology | None | Co-Infections | None | ||||||||||
| DLS16-67598 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 42 Y | M | Asian | <-70C | 27-Apr-17 | Roche Cobas | 12,100,000 IU/mL | 27-Apr-17 | Real Time PCR | 1 | 5-May-17 | 3-series HepB Vaccine | Yes | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | IV Drug Abuse | Symptoms | Itching; Depression | Additional Testing | ALT: 68 U/L | AST: 42 U/L | Bilirubin: 14.2 umol/L | Serum Creatinine: 62 umol/L | 26-Mar-17 | Hepatitis Serology | None | Co-Infections | HIV+ | 1-Jul-2005 | CD4 - 190 15-Sep-2016 | ||||||||||
| DLS16-67516 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 18.00 | $95.00 | 63 Y | M | Asian | <-70C | 10-May-17 | Roche Cobas | 30,300,000 IU/mL | 10-May-17 | Real Time PCR | 1 | 15-May-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 111 U/L | AST: 214 U/L | Bilirubin: 18.4 umol/L | Serum Creatinine: 78 umol/L | 5-May-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | 4-May-2017 | Co-Infections | None | |||||||||
| DLS16-67555 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 35 Y | M | Asian | <-70C | 15-May-17 | Roche Cobas | 50,100 IU/mL | 25-May-17 | Real Time PCR | 1 | 23-May-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Itching; Sleep disturbances | Additional Testing | ALT: 36 U/L | AST: 52 U/L | Bilirubin: 12 umol/L | Serum Creatinine: 76 umol/L | 4-May-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | Co-Infections | None | ||||||||||
| DLS16-67647 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 14.00 | $95.00 | 39 Y | M | Asian | <-70C | 18-May-17 | Roche Cobas | 3,260,000 IU/mL | 18-May-17 | Real Time PCR | 1 | 25-May-17 | 3-series HepB Vaccine | no | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Abdominal pain; Night sweats; Dark urine; Fatigue; Sleep disturbances | Additional Testing | ALT: 52 U/L | AST: 37 U/L | Serum Creatinine: 74 umol/L | 12-May-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | 12-May-2017 | Co-Infections | None | |||||||||
| DLS16-67530 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 38 Y | M | Asian | <-70C | 22-May-17 | Roche Cobas | 5,000,000 IU/mL | 22-May-17 | Real Time PCR | 1 | 25-May-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Itching; Night sweats; Unexplained weight loss; Fatigue; Flu-like symptoms | Additional Testing | ALT: 26 U/L | AST: 37 U/L | Bilirubin: 12 umol/L | Serum Creatinine: 73 umol/L | 12-May-17 | Hepatitis Serology | None | Co-Infections | None | ||||||||||
| DLS16-67526 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 43 Y | M | Asian | <-70C | 22-May-17 | Roche Cobas | 11,600,000 IU/mL | 22-May-17 | Real Time PCR | 1 | 25-May-17 | 3-series HepB Vaccine | Yes | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 45 U/L | AST: 34 U/L | Serum Creatinine: 114 umol/L | 8-May-17 | Hepatitis Serology | None | Co-Infections | None | ||||||||||
| DLS16-67464 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 17.00 | $95.00 | 32 Y | F | Asian | <-70C | 23-Jun-17 | Roche Cobas | 260,000 IU/mL | 23-Jun-17 | Real Time PCR | 1 | 20-Jun-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Abdominal pain; Fatigue | Additional Testing | ALT: 48 U/L | AST: 82 U/L | Bilirubin: 28 umol/L | Serum Creatinine: 62 umol/L | 20-Jun-17 | Hepatitis Serology | None | Co-Infections | None | ||||||||||
| DLS16-67570 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 47 Y | M | Asian | <-70C | 22-Jun-17 | Roche Cobas | 5,000,000 IU/mL | 22-Jun-17 | Real Time PCR | 1 | 26-Jun-17 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 68 U/L | AST: 72 U/L | 22-Jun-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | 18-Jun-2017 | Co-Infections | None | |||||||||
| DLS16-72214 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 51 Y | F | White | <-70C | 14-Nov-17 | Roche cobas | 579,000 IU/mL | 14-Jul-17 | Siemens TruGene HCV 5NC | 1b | 14-Jul-17 | HCV Date of Diagnosis | 10-Aug-92 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 152 U/L | AST: 40 U/L | 14-Jul-2017 | Bilirubin: 0.36 mg/dL | Serum Creatinine: 0.65 mg/dL | Chronic Hepatitis C | 14-Nov-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb-, | 15-Nov-17 | Co-Infections | None | |||||||
| DLS16-72183 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 15.00 | $95.00 | 48 Y | F | White | <-70C | 27-Jun-17 | Roche cobas | 783,000 IU/mL | 21-Mar-17 | Siemens TruGene HCV 5NC | 1b | 21-Mar-17 | HCV Date of Diagnosis | 1-Feb-94 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 38 U/L | AST: 38 U/L | | Bilirubin: 0.69 mg/dL | Serum Creatinine: 0.86 mg/dL | Chronic Hepatitis C | 27-Jun-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 27-Jun-17 | Co-Infections | None | |||||||
| DLS16-72199 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 10.00 | $95.00 | 72 Y | F | White | <-70C | 17-Jul-17 | Roche cobas | 148,000 IU/mL | 8-May-17 | Siemens TruGene HCV 5NC | 1b | 8-May-17 | HCV Date of Diagnosis | 9-Mar-97 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 38 U/L | AST: 38 U/L | | Bilirubin: 0.48 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C | 17-Jul-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 8-May-17 | Co-Infections | None | |||||||
| DLS0025511 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 41 Y | M | White | <-70C | 27-Nov-17 | Roche cobas | 650,000 IU/mL | 6-Sep-17 | Siemens TruGene HCV 5NC | 1b | 1-Sep-15 | HCV Date of Diagnosis | 16-Nov-09 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 20 U/L | AST: 28 U/L | Bilirubin: 1.5 mg/dL | Serum Creatinine: 1.04 mg/dL | 13-Jul-2010 | Biopsy | HAI = 7 FIB1 ST3 Chronic Hepatitis C | 6-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb-, | 6-Sep-17 | Co-Infections | None | |||||||
| DLS16-72217 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 6.00 | $95.00 | 54 Y | M | White | <-70C | 11-Oct-17 | Roche cobas | 445,000 IU/mL | 11-Oct-17 | Siemens TruGene HCV 5NC | 1b | 19-May-10 | HCV Date of Diagnosis | 19-Mar-10 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 26 U/L | 28-Mar-2017 | AST: 84 U/L | | Bilirubin: 3.54 mg/dL | Serum Creatinine: 0.7 mg/dL | Liver Cirrhosis from HCV | 26-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 28-Mar-17 | Co-Infections | None | |||||||
| DLS0025504 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 6.00 | $95.00 | 53 Y | F | White | <-70C | 27-Nov-17 | Roche cobas | 6,780,000 IU/mL | 8-Sep-17 | Siemens TruGene HCV 5NC | 1b | 8-Sep-17 | HCV Date of Diagnosis | 3-Jul-10 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 20 U/L | AST: 30 U/L | Bilirubin: 0.56 mg/dL | Serum Creatinine: 0.71 mg/dL | Chronic Hepatitis C | 16-Jun-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb-, HBeAg-, | 8-Sep-17 | Co-Infections | None | |||||||
| DLS0025509 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 52 Y | F | White | <-70C | 27-Nov-17 | Roche cobas | 880,000 IU/mL | 13-Oct-17 | Siemens TruGene HCV 5NC | 1b | 13-Oct-17 | HCV Date of Diagnosis | 29-Aug-13 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 40 U/L | AST: 24 U/L | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.7 mg/dL | 29-Aug-2013 | Biopsy HAI = 6 FIB2 Chronic Hepatitis C | 13-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 13-Oct-17 | Co-Infections | None | |||||||
| DLS16-72188 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 14.00 | $95.00 | 59 Y | F | White | <-70C | 20-Sep-17 | Roche cobas | 58,500 IU/mL | 29-Sep-16 | Siemens TruGene HCV 5NC | 1b | 9-Dec-13 | HCV Date of Diagnosis | 9-Dec-13 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 50 U/L | AST: 50 U/L | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 13-Jul-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, | 13-Jul-17 | Co-Infections | None | |||||||
| DLS16-72197 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 14.00 | $95.00 | 81 Y | M | White | <-70C | 18-Oct-17 | Roche cobas | 1,200,000 IU/mL | 16-Oct-17 | Siemens TruGene HCV 5NC | 1b | 16-Oct-16 | HCV Date of Diagnosis | 2-Feb-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 56 U/L | AST: 55 U/L | ALP: 56 U/L | Bilirubin: 0.63 mg/dL | Serum Creatinine: 0.99 mg/dL | Chronic Hepatitis C | 4-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 16-Oct-17 | Co-Infections | None | |||||||
| DLS16-72194 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 17.00 | $95.00 | 76 Y | M | White | <-70C | 13-Jul-17 | Roche cobas | 606,130 IU/mL | 2-Sep-16 | Siemens TruGene HCV 5NC | 1b | 11-Jan-17 | HCV Date of Diagnosis | 1-Mar-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 36 U/L | AST: 42 U/L | | Bilirubin: 1.8 mg/dL | Serum Creatinine: 0.76 mg/dL | Liver Cirrhosis from HCV | 13-Jul-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb+, | 5-May-17 | Co-Infections | None | |||||||
| DLS16-72185 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 68 Y | F | White | <-70C | 21-Nov-17 | Roche cobas | 6,500,000 IU/mL | 10-May-17 | Siemens TruGene HCV 5NC | 1b | 11-Mar-15 | HCV Date of Diagnosis | 11-Mar-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 44 U/L | AST: 48 U/L | Serum Creatinine: 0.9 mg/dL | Chronic Hepatitis C | 4-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, | 4-Sep-17 | Co-Infections | None | |||||||
| DLS16-72207 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 69 Y | M | White | <-70C | 27-Sep-17 | Roche cobas | 319,000 IU/mL | 3-May-17 | Siemens TruGene HCV 5NC | 1b | 3-May-17 | HCV Date of Diagnosis | 8-May-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 40 U/L | AST: 88 U/L | Bilirubin: 0.51 mg/dL | Serum Creatinine: 1.0 mg/dL | | 3-May-2017 | ALP: 111 U/L | Chronic Hepatitis C | 27-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, | 3-May-17 | Co-Infections | None | |||||||
| DLS16-72198 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 50 Y | F | White | <-70C | 27-Jul-17 | Roche cobas | 3,000,000 IU/mL | 4-Feb-17 | Siemens TruGene HCV 5NC | 1b | 10-Jun-15 | HCV Date of Diagnosis | 10-Jun-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 40 U/L | AST: 38 U/L | | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C | 27-Jul-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 4-Feb-17 | Co-Infections | None | |||||||
| DLS16-72210 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 14.00 | $95.00 | 76 Y | F | White | <-70C | 25-Oct-17 | Roche cobas | 2,120,000 IU/mL | 1-Sep-17 | Siemens TruGene HCV 5NC | 1b | 1-Oct-17 | HCV Date of Diagnosis | 10-Aug-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 42 U/L | AST: 42 U/L | Serum Creatinine: 0.7 mg/dL | 31-Aug-2017 | Bilirubin: 0.5 mg/dL | Chronic Hepatitis C | 19-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb+, | 31-Aug-17 | Co-Infections | None | |||||||
| DLS16-72200 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 4.00 | $95.00 | 82 Y | M | White | <-70C | 09-Jun-17 | Roche cobas | 913,750 IU/mL | 22-May-17 | Siemens TruGene HCV 5NC | 1b | 22-Sep-15 | HCV Date of Diagnosis | 22-Sep-15 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 100 U/L | AST: 120 U/L | | Bilirubin: 1.2 mg/dL | Serum Creatinine: 1.8 mg/dL | Liver Cirrhosis from HCV | 22-May-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb+, | 22-May-17 | Co-Infections | None | |||||||
| DLS16-72186 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 65 Y | F | White | <-70C | 27-Jul-17 | Roche cobas | 3,700,000 IU/mL | 10-Feb-17 | Siemens TruGene HCV 5NC | 1b | 23-Feb-16 | HCV Date of Diagnosis | 10-Feb-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 40 U/L | AST: 40 U/L | | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 20-Jun-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb-, | 23-Feb-17 | Co-Infections | None | |||||||
| DLS16-72216 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 64 Y | F | White | <-70C | 13-Oct-17 | Roche cobas | 1,300,000 IU/mL | 5-Apr-17 | Siemens TruGene HCV 5NC | 1b | 3-May-17 | HCV Date of Diagnosis | 16-Jun-16 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 20 U/L | AST: 35 U/L | 5-Apr-2017 | Bilirubin: 0.7 mg/dL | 29-Sep-2017 | Serum Creatinine: 0.69 mg/dL | 24-Mar-2016 | Biopsy HAI=12 Chronic Hepatitis C | 13-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBcAb+ | 3-May-17 | Co-Infections | None | |||||||
| DLS16-72189 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 71 Y | F | White | <-70C | 05-Oct-17 | Roche cobas | 390,000 IU/mL | 14-Mar-17 | Siemens TruGene HCV 5NC | 1b | 17-Mar-17 | HCV Date of Diagnosis | 14-Mar-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 40 U/L | AST: 46 U/L | ALP: 46 U/L | Bilirubin: 1.1 mg/dL | 16-Jan-2017 Serum Creatinine: 0.9 mg/dL | Chronic Hepatitis C | 31-Aug-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, HBeAb+, | 16-Jan-17 | Co-Infections | None | |||||||
| DLS16-72209 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 55 Y | F | White | <-70C | 13-Sep-17 | Roche cobas | 654,234 IU/mL | 24-Apr-17 | Siemens TruGene HCV 5NC | 1b | 24-Apr-17 | HCV Date of Diagnosis | 24-Apr-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 20 U/L | AST: 24 U/L | | Bilirubin: 1.5 mg/dL | Serum Creatinine: 0.82 mg/dL | Chronic Hepatitis C | 11-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 24-Apr-17 | Co-Infections | None | |||||||
| DLS16-72206 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 6.00 | $95.00 | 73 Y | F | White | <-70C | 06-Sep-17 | Roche cobas | 965,000 IU/mL | 7-Jul-17 | Siemens TruGene HCV 5NC | 1b | 7-Jul-17 | HCV Date of Diagnosis | 27-Jun-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 140 U/L | AST: 96 U/L | Bilirubin: 1.2 mg/dL | Serum Creatinine: 0.69 mg/dL | | 4-Mar-2017 | ALP: 171 U/L | Liver Cirrhosis from Chronic HCV | 2-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, | 6-Apr-17 | Co-Infections | None | |||||||
| DLS16-72203 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 69 Y | F | White | <-70C | 05-Oct-17 | Roche cobas | 3,200,000 IU/mL | 15-Sep-17 | Siemens TruGene HCV 5NC | 1b | 30-Aug-17 | HCV Date of Diagnosis | 26-Jul-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 84 U/L | AST: 60 U/L | 3-Jul-2017 | Bilirubin: 0.62 mg/dL | Serum Creatinine: 0.74 mg/dL | Chronic Hepatitis C | 3-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, HBeAg-, HBeAb+, | 15-Sep-17 | Co-Infections | None | |||||||
| DLS16-72212 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 9.00 | $95.00 | 53 Y | M | White | <-70C | 25-Oct-17 | Roche cobas | 2,810,000 IU/mL | 29-Aug-17 | Siemens TruGene HCV 5NC | 1b | 29-Aug-17 | HCV Date of Diagnosis | 29-Aug-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 32 U/L | AST: 48 U/L | ALP: 51 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 29-Aug-17 | Diasorin Liaison Serology Results | HBsAg-, HBcAb+, | 29-Aug-17 | Co-Infections | None | |||||||
| DLS0025505 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 70 Y | F | White | <-70C | 27-Nov-17 | Roche cobas | 856,000 IU/mL | 14-Sep-17 | Siemens TruGene HCV 5NC | 1b | 14-Sep-17 | HCV Date of Diagnosis | 14-Sep-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 35 U/L | AST: 52 U/L | Bilirubin: 0.7 mg/dL | Serum Creatinine: 0.9 mg/dL | Chronic Hepatitis C | 14-Sep-17 | Diasorin Liaison Serology Results | HBsAg-, HBcAb-, | 14-Sep-17 | Co-Infections | None | |||||||
| DLS16-72213 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 76 Y | F | White | <-70C | 25-Oct-17 | Roche cobas | 1,060,000 IU/mL | 16-Oct-17 | Siemens TruGene HCV 5NC | 1b | 16-Oct-17 | HCV Date of Diagnosis | 16-Oct-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 28 U/L | AST: 52 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.8 mg/dL | Chronic Hepatitis C | 16-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-, | 7-Nov-17 | Co-Infections | None | |||||||
| DLS16-72191 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 59 Y | M | White | <-70C | 14-Nov-17 | Roche cobas | 10,900,000 IU/mL | 17-Oct-17 | Siemens TruGene HCV 5NC | 1a | 17-Oct-17 | HCV Date of Diagnosis | 17-Oct-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 16 U/L | AST: 24 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.8 mg/dL | Chronic Hepatitis C | 17-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb-, HBcAb-,, HBeAb-, | 17-Jul-17 | Co-Infections | None | |||||||
| DLS16-67531 | Hepatitis C (HCV) Genotype 1 | Vietnam | Serum | 1.00 | 16.00 | $95.00 | 60 Y | M | Asian | <-70°C | 26-Apr-17 | Roche Cobas | 2,990,000 IU/mL | 26-Apr-2017 | Real Time PCR | Genotype 1 | 28-Apr-2017 | 3-series HepB Vaccine | No | $95.00 | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 62 U/L | AST: 78 U/L | Bilirubin: 62 umol/L | Serum Creatinine: 60 umol/L | 20-Apr-2017 | Hepatitis Serology | HCV Ab + | 27-Apr-2017 | Co-Infections | None | |||||||||
| DLS0025506 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 48 Y | F | White | <-70C | 20-Dec-17 | Roche cobas | 3,880,000 IU/mL | HCV Viral Load | Genotype | 1b | 19-Oct-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 35 U/L | AST: 35 U/L | Bilirubin: 0.46 mg/dL | 19-Oct-2017 | Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 23-Sep-17 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- |HBeAg- (CMIA) | 19-Oct-17 | Co-Infections | None | |||||||||
| DLS0025520 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 10.00 | $95.00 | 52 Y | F | White | <-70C | 20-Dec-17 | Roche cobas | 639,000 IU/mL | HCV Viral Load | Genotype | 1a | 27-Oct-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | Fatigue | Additional Testing | ALP: 73 U/L | Bilirubin: 0.72 mg/dL | Creatinine: 1.02 mg/dL | Chronic Hepatitis C | 27-Oct-17 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb- | (CMIA) | 27-Oct-17 | Co-Infections | None | |||||||||
| DLS0025508 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 9.00 | $95.00 | 64 Y | F | White | <-70C | 30-Jan-18 | Roche cobas | 17,500,000 IU/mL | HCV Viral Load | Genotype | 1b | 17-Nov-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 18 U/L | AST: 22 U/L | Bilirubin: 0.7 mg/dL | Creatinine: 0.76 mg/dL | Chronic Hepatitis C | 8-Nov-17 | Hepatitis Serology | HBsAg- | 12-Dec-2017 | HBsAb+ | HBcAb+ | 17-Nov-2017 (CMIA) | Co-Infections | None | |||||||||
| DLS0025513 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 6.00 | $95.00 | 42 Y | M | White | <-70C | 17-Jan-18 | Roche cobas | 7,290,000 IU/mL | HCV Viral Load | Genotype | 1b | 17-Jan-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 110 U/L | AST: 130 U/L | Bilirubin: 0.6 mg/dL | Creatinine: 0.7 mg/dL | Chronic Hepatitis C | 23-Nov-17 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb- | (CMIA) | 23-Nov-17 | Co-Infections | None | |||||||||
| DLS0025510 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 9.00 | $95.00 | 57 Y | M | White | <-70C | 12-Jan-18 | Roche cobas | 3,090,000 IU/mL | HCV Viral Load | Genotype | 1b | 15-Jun-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 100 U/L | AST: 60 U/L | Bilirubin: 0.8 mg/dL | Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 28-Nov-17 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 28-Nov-17 | Co-Infections | None | |||||||||
| DLS0025502 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 11.00 | $95.00 | 73 Y | M | White | <-70C | 20-Dec-17 | Roche cobas | 8,970,000 IU/mL | HCV Viral Load | Genotype | 1b | 7-Jul-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | Fatigue | Additional Testing | ALT: 91 U/L | AST: 55 U/L | Creatinine: 1.04 mg/dL | Chronic Hepatitis C | 11-Dec-17 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) | 11-Aug-17 | Co-Infections | None | |||||||||
| DLS0025512 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 45 Y | F | White | <-70C | 17-Jan-18 | Roche cobas | 61,000 IU/mL | HCV Viral Load | Genotype | 1b | 21-Dec-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.6 mg/dL | Creatinine: 0.4 mg/dL | Chronic Hepatitis C | 21-Dec-17 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 21-Dec-17 | Co-Infections | None | |||||||||
| DLS0083204 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 10.00 | $95.00 | 78 Y | M | White | <-70C | 22-Mar-18 | Roche cobas | 4,000,000 IU/mL | HCV Viral Load | Genotype | 1b | 12-Jan-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | Fatigue | Additional Testing | Bilirubin: 0.5 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C | 12-Jan-18 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) | 12-Jan-18 | Co-Infections | None | |||||||||
| DLS0025514 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 8.00 | $95.00 | 53 Y | M | White | <-70C | 23-Jan-18 | Roche cobas | 13,200,000 IU/mL | HCV Viral Load | Genotype | 1b | 27-May-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 108 U/L | AST: 56 U/L | Bilirubin: 0.76 mg/dL | Chronic Hepatitis C | 23-Jan-18 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) | 27-May-17 | Co-Infections | None | |||||||||
| DLS0025507 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 66 Y | F | White | <-70C | 08-Mar-18 | Roche cobas | 90,560 IU/mL | HCV Viral Load | Genotype | 1b | 10-Feb-16 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | Transfusion | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 103 U/L | AST: 55.5 U/L | Bilirubin: 1.5 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C | 3-Feb-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 10-Jan-18 | Co-Infections | None | |||||||||
| DLS0083205 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 48 Y | F | White | <-70C | 05-Apr-18 | Roche cobas | 12,500,000 IU/mL | HCV Viral Load | Genotype | 1b | 9-Feb-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.5 mg/dL | Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 9-Feb-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb+ | (CMIA) | 9-Feb-18 | Co-Infections | None | |||||||||
| DLS0025503 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 14.00 | $95.00 | 61 Y | F | White | <-70C | 08-Mar-18 | Roche cobas | 227 IU/mL | HCV Viral Load | Genotype | 1b | 10-Feb-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | Fatigue | Additional Testing | ALT: 73 U/L | AST: 103 U/L | Bilirubin: 1.5 mg/dL | Creatinine: 1.1 mg/dL | Chronic Hepatitis C | 4-Mar-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 6-Dec-17 | Co-Infections | None | |||||||||
| DLS0083211 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 65 Y | M | White | <-70C | 08-May-18 | Roche cobas | 1,190,000 IU/mL | HCV Viral Load | Genotype | 1b | 26-Mar-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 1.04 mg/dL | Creatinine: 0.8 mg/dL | Chronic Hepatitis C | 14-Mar-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb+ | (CMIA) | 14-Mar-18 | Co-Infections | None | |||||||||
| DLS0083210 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 33 Y | F | White | <-70C | 02-May-18 | Roche cobas | 541,300 IU/mL | HCV Viral Load | Genotype | 1a | 15-Mar-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.3 mg/dL | Creatinine: 0.77 mg/dL | Chronic Hepatitis C | 15-Mar-18 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) | 15-Mar-18 | Co-Infections | None | |||||||||
| DLS0083206 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 12.00 | $95.00 | 70 Y | F | White | <-70C | 09-Apr-18 | Roche cobas | 1,000,000 IU/mL | HCV Viral Load | Genotype | 1b | 21-Nov-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 36.4 U/L | AST: 34.5 U/L | Bilirubin: 0.95 mg/dL | Creatinine: 0.65 mg/dL | Chronic Hepatitis C | 21-Mar-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 21-Mar-18 | Co-Infections | None | |||||||||
| DLS0083207 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 70 Y | M | White | <-70C | 13-Apr-18 | Roche cobas | 290,000 IU/mL | HCV Viral Load | Genotype | 1b | 13-Sep-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.7 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C | 26-Mar-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 6-Apr-18 | Co-Infections | None | |||||||||
| DLS0025517 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 5.00 | $95.00 | 58 Y | M | White | <-70C | 15-Mar-18 | Roche cobas | 470,000 IU/mL | HCV Viral Load | Genotype | 1b | 3-Jan-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.6 mg/dL | Creatinine: 0.8 mg/dL | Chronic Hepatitis C | 27-Mar-18 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 26-Jan-18 | Co-Infections | None | |||||||||
| DLS0083208 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 7.00 | $95.00 | 57 Y | M | White | <-70C | 18-Apr-18 | Roche cobas | 212 IU/mL | HCV Viral Load | Genotype | 1a | 5-Jun-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.78 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C | 9-Apr-18 | Hepatitis Serology | HBsAg- | HBsAb+ | 6-Nov- (CMIA) | 2017 | Co-Infections | None | |||||||||
| DLS0083209 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 10.00 | $95.00 | 70 Y | F | White | <-70C | 27-Apr-18 | Roche cobas | 9,550,000 IU/mL | HCV Viral Load | Genotype | 1a | 15-Jan-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.7 mg/dL | Creatinine: 0.6 mg/dL | Chronic Hepatitis C | 20-Apr-18 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) | 15-Jun-17 | Co-Infections | None | |||||||||
| DLS0083214 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 71 Y | F | White | <-70C | 12-Jun-18 | Roche cobas | 7,980,000 IU/mL | HCV Viral Load | Genotype | 1b | 10-Jan-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | Fatigue | Additional Testing | Bilirubin: 1.8 mg/dL | Creatinine: 0.7 mg/dL | Chronic Hepatitis C | 30-May-18 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb- | (CMIA) | 10-Jan-18 | Co-Infections | None | |||||||||
| DLS0083218 | Hepatitis C (HCV) Genotype 1 | Italy | Serum | 1.00 | 13.00 | $95.00 | 76 Y | F | White | <-70C | 26-Jul-18 | Roche cobas | 6,000,000 IU/mL | HCV Viral Load | Genotype | 1b | 31-May-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | ALT: 230 U/L | AST: 200 U/L | Bilirubin: 2.76 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C | 22-Jun-18 | Hepatitis Serology | HBsAg- | HBsAb- | CMIA) | 31-May-18 | Co-Infections | None |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.